Medtronic’s move to turn its diabetes division into a separate company allows it to step away from a lower-profit, ...

Medical-device maker Medtronic plans to separate its diabetes business into a stand-alone company, the company said, in a ...

Finally, Medtronic remains an excellent dividend stock, and it recently announced yet another payout hike. The medical device ...

Global medical device company Medtronic announced Wednesday that it intends to separate its diabetes business into a ...

Medtronic plans to separate from its diabetes business and launch it as an independent company—one that will count more than ...

CEO Geoff Martha told investors the split simplifies Medtronic’s portfolio, while creating a stand-alone diabetes tech ...

Medtronic anticipates the separation of its diabetes business unit into a wholly separate entity to complete within 18 months ...

The medical device giant, which is domiciled in Dublin, Ireland but has its main office in Fridley, Minnesota, confirmed that ...

While some analysts questioned why Medtronic would leave a fast-growing market, others backed the company’s plan to focus on ...

Medtronic upgraded to 'Strong Buy' with $104 fair value. Diabetes spin-off boosts focus on core markets, driving growth, ...

The new diabetes company will be predominantly business-to-consumer, while Medtronic’s model was more business-to-business.

Medtronic’s decision to spin out its diabetes division into a separate entity marks a major shift — one that allows the medical device giant to shed a lower-margin, consumer-facing business ...